München
03.10.25 | 08:02
17,100 Euro
-8,06 % -1,500
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug | 4 | Seeking Alpha | ||
| Do | Nanobiotix stock jumps on positive esophageal cancer treatment data | 2 | Investing.com | ||
| Do | Positive Studiendaten zu Speiseröhrenkrebs-Therapie beflügeln Nanobiotix-Aktie | - | Investing.com Deutsch | ||
| Mi | Nanobiotix S.A.: NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer | 93 | GlobeNewswire (Europe) | Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective... ► Artikel lesen | |
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Mi | Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M | 1 | Seeking Alpha | ||
| Mi | Leerink Partners raises Nanobiotix stock price target to $24 on pipeline progress | 1 | Investing.com | ||
| Di | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results | 577 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches... ► Artikel lesen | |
| Di | Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer | 8 | Benzinga.com | ||
| Di | Nanobiotix stock soars after promising cancer treatment results | 3 | Investing.com | ||
| Di | Nanobiotix S.A.: NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC | 173 | GlobeNewswire (Europe) | Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and... ► Artikel lesen | |
| Di | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.09. | Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday | 7 | Benzinga.com | ||
| 18.09. | Nanobiotix soars on positive phase 1 results for JNJ-1900 in melanoma | 23 | Seeking Alpha | ||
| 17.09. | Nanobiotix S.A.: NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant ... | 451 | GlobeNewswire (Europe) | Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase... ► Artikel lesen | |
| 12.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.09. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 27.08. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.08. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 11.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 07.07. | Nanobiotix S.A.: NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) | 718 | GlobeNewswire (Europe) | Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
| COSCIENS BIOPHARMA | 2,060 | -3,74 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 58,20 | -0,10 % | Halozyme Therapeutics, Inc.: Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 5,144 | +1,18 % | Why Did AbCellera's Stock Jump Over 7% After Hours? | ||
| GLOW LIFETECH | 0,029 | +11,76 % | Glow Lifetech to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the company is participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 256,30 | -0,31 % | BIO-RAD LABORATORIES, INC. - 8-K, Current Report | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
| BIOLINERX | 3,080 | -4,35 % | BioLineRx partners with Hemispherian to advance brain cancer therapy | ||
| WHITEHAWK THERAPEUTICS | 1,590 | -5,36 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,780 | -0,56 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,590 | +1,27 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,800 | -0,52 % | Applied Therapeutics Provides Update Following Meeting with FDA | NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - 8-K, Current Report |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,06 % bei einem Aktienkurs von 17,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.